We are monitoring the impact of COVID-19 on Latin America Ovarian Cancer Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1395
Share on
Share on

Latin America Ovarian Cancer Market Research Report – Segmented By Stage Of Cancer, Cancer Type, Diagnosis, Type Of Treatment & Country (Brazil, Argentina, Chile, Mexico and Rest of Latin America) – Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1395
Pages: 181

Latin America Ovarian Cancer Market Size (2021 to 2026)

The Latin American Ovarian Cancer Market size is estimated to grow at a steady rate between 2021 to 2026.

The increase in the prevalence of new ovarian cases and the rising need for more effective treatment are the major factors driving the Latin American ovarian cancer market. Also, the increasing geriatric population, rising use of new drugs and therapies, and increasing healthcare spending are expected to propel the market growth. Mutagenic alterations in the DNA are the cause of ovarian cancer. Inherited genetic abnormalities cause ovarian cancer. The risk of getting ovarian cancer is considerable if a woman has inherited mutations in the BRCA1 and BRCA2 genes.

The most common form of ovarian cancer is epithelial ovarian cancer (EOC), which arises from the epithelium of the ovary. Ovarian cancer is a kind of cancer that affects a lot of women. It kills more women than any other cancer of the female genital system, and it ranks fifth in overall cancer mortality among women. Because this kind of cancer is rarely detected early, therapy might be challenging at an advanced stage. Ovarian cancer is the seventh-commonest cancer among women. Increased cancer risk factors have resulted in an upward trend in cancer incidence throughout the world. Ovarian cancer was responsible for 4.4 percent of all cancer-related deaths among women in the recent past. 

Additionally, the pharmaceutical companies in emerging countries such as Brazil and Mexico invest in the research and development of innovative products such as combination drugs to reduce manufacturing costs, improve medication concordance, reduce side effects, and increase profitability. 

However, the Latin American market for ovarian cancer drugs is expected to be hindered by the growing use of biologics and targeted treatments. Targeted treatments work as drug replacements by identifying and attacking cancer cells rather than normal ones.

This research report on the Latin American ovarian cancer market has been segmented and sub-segmented into the following categories:

By Stage of Cancer:

  • Stage I
    • Stage IA
    • Stage IB
    • Stage IC
  • Stage II
    • Stage IIA
    • Stage IIB
    • Stage IIC
  • Stage III
    • Stage IIIA
    • Stage IIIB
    • Stage IIIC
  • Stage IV

By Cancer Type:

  • Primary Peritoneal Carcinoma
  • Ovarian Stromal Tumors
  • Ovarian Germ Cell Tumors
  • Epithelial Ovarian Tumors

By Diagnosis:

  • Physical Examination
  • Blood Tests
  • Ultrasound
  • PET
  • CT Scan
  • MRI
  • Human Chorionic Gonadotropin Test
  • Biopsy

By Type of Treatment:

  • Chemotherapy
  • Radiation Therapy
  • Hormonal Therapy
  • Surgery
  • Immunotherapy
  • Targeted Therapy

By Country:

  • Mexico
  • Brazil
  • Argentina
  • Chile
  • Rest of Latin America

Geographically, the Latin American market is expected to account for a moderate share in the global ovarian cancer market during the forecast period. The market growth is attributed to many therapeutics in the development stage and the presence of market competition regional-wide. However, the growing geriatric population among women is a significant concern because women in this age group had the lowest survival rate; therefore, the aging population is expected to increase the market growth in the region. Drugs like Bevacizumab (Avastin) and Pazopanib (Votrient) are expected to increase the market, dominated by generics like paclitaxel and carboplatin. In addition, improving healthcare infrastructure and healthcare facilities in Latin America are further likely to influence the market growth. In Latin American regional market. The countries such as Mexico and Brazil are contributing to the regional market growth. In addition, the factors such as increasing government funding and proliferation of ovarian cases augment the market growth. Over the forecast period, Mexico has witnessed a significant share in the Ovarian Cancer Therapeutics Market owing to the rising burden of ovarian cancer and increasingly innovating and developing combination drugs to treat ovarian cancer drugs.

KEY MARKET PLAYERS:

A few of the prominent companies operating in the Latin American ovarian cancer market profiled in this report are Aetera Zenteris Inc., Eli Lilly and Company, Roche, Amgen, Janssen Pharmaceuticals, Inc., Bristol Myers Squibb Company, Novogen GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, and Genentech Inc.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Stage Of Cancer                        

                                5.1.1 Stage I       

                                                5.1.1.1 Stage IA

                                                5.1.1.2 Stage IB

                                                5.1.1.3 Stage IC

                                5.1.2 Stage II     

                                                5.1.2.1 Stage IIA

                                                5.1.2.2 Stage IIB

                                                5.1.2.3 Stage IIC

                                5.1.3 Stage III    

                                                5.1.3.1 Stage IIIA

                                                5.1.3.2 Stage IIIB

                                                5.1.3.3 Stage IIIC

                                5.1.4 Stage IV    

                                5.1.5 Y-o-Y Growth Analysis, By Stage Of Cancer

                                5.1.6 Market Attractiveness Analysis, By Stage Of Cancer               

                                5.1.7 Market Share Analysis, By Stage Of Cancer

                5.2 Type                              

                                5.2.1 Introduction           

                                5.2.2 Primary Peritoneal Carcinoma        

                                5.2.3 Ovarian Stromal Tumors   

                                5.2.4 Ovarian Germ Cell Tumors

                                5.2.5 Epithelial Ovarian Tumors

                                5.2.6 Y-o-Y Growth Analysis, By Type      

                                5.2.7 Market Attractiveness Analysis, By Type     

                                5.2.8 Market Share Analysis, By Type      

                5.3 Diagnosis                     

                                5.3.1 Introduction           

                                5.3.2 Physical Examination          

                                5.3.3 Blood Tests             

                                5.3.4 Ultrasound             

                                5.3.5 PET             

                                5.3.6 CT Scan     

                                5.3.7 MRI            

                                5.3.8 Human Chorionic Gonadotropin Test          

                                5.3.9 Biopsy       

                                5.3.10 Y-o-Y Growth Analysis, By Diagnosis          

                                5.3.11 Market Attractiveness Analysis, By Diagnosis         

                                5.3.12 Market Share Analysis, By Diagnosis          

                5.4 Treatment                  

                                5.4.1 Introduction           

                                5.4.2 Chemotherapy     

                                5.4.3 Radiation Therapy

                                5.4.4 Hormonal Therapy              

                                5.4.5 Surgery    

                                5.4.6 Immunotherapy   

                                5.4.7 Targeted Therapy

                                5.4.8 Y-o-Y Growth Analysis, By Treatment          

                                5.4.9 Market Attractiveness Analysis, By Treatment         

                                5.4.10 Market Share Analysis, By Treatment       

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Stage of Cancer

                                                6.1.3.3 By Type

                                                6.1.3.4 By Diagnosis

                                                6.1.3.5 By Treatment

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.3.2 By Stage of Cancer

                                                6.1.3.3 By Type

                                                6.1.3.4 By Diagnosis

                                                6.1.3.5 By Treatment

                                6.1.5 Market Share Analysis        

                                                6.1.5.1 By Geographical Area

                                                6.1.3.2 By Stage of Cancer

                                                6.1.3.3 By Type

                                                6.1.3.4 By Diagnosis

                                                6.1.3.5 By Treatment

                6.2 Brazil                             

                6.3 Mexico                         

                6.4 Rest of Latin America                             

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 Aetera Zenteris Inc.                

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Eli Lilly and Company                             

                8.3 Roche                           

                8.4 Amgen                         

                8.5 Janssen Pharmaceuticals, Inc.                             

                8.6 Bristol Myers Squibb Company                          

                8.7 Novogen, Inc.                            

                8.8 GlaxoSmithKline                      

                8.9 Boehringer Ingelheim                            

                8.10 AstraZeneca                            

                8.11 Genentech Inc.                       

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Latin America Ovarian Cancer Market, By Stage Of Cancer, From 2020 to 2025 (USD Million)
  2. Latin America Stage I Market, By Region, From 2020 to 2025 (USD Million)
  3. Latin America Stage II Market, By Region, From 2020 to 2025 (USD Million)
  4. Latin America Stage III Market, By Region, From 2020 to 2025 (USD Million)
  5. Latin America Stage IV Market, By Region, From 2020 to 2025 (USD Million)
  6. Latin America Ovarian Cancer Market, By Cancer Type, From 2020 to 2025 (USD Million)
  7. Latin America Primary Peritoneal Carcinoma Market, By Region, From 2020 to 2025 (USD Million)
  8. Latin America Ovarian Stromal Tumors Market, By Region, From 2020 to 2025 (USD Million)
  9. Latin America Ovarian Germ Cell Tumors Market, By Region, From 2020 to 2025 (USD Million)
  10. Latin America Epithelial Ovarian Tumors Market, By Region, From 2020 to 2025 (USD Million)
  11. Latin America Ovarian Cancer Market, By Diagnosis, From 2020 to 2025 (USD Million)
  12. Latin America Physical Examination Market, By Region, From 2020 to 2025 (USD Million)
  13. Latin America Blood Tests Market, By Region, From 2020 to 2025 (USD Million)
  14. Latin America Ultrasound Market, By Region, From 2020 to 2025 (USD Million)
  15. Latin America PET Market, By Region, From 2020 to 2025 (USD Million)
  16. Latin America CT Scan Market, By Region, From 2020 to 2025 (USD Million)
  17. Latin America MRI Market, By Region, From 2020 to 2025 (USD Million)
  18. Latin America Human Chorionic Gonadotropin Test Market, By Region, From 2020 to 2025 (USD Million)
  19. Latin America Biopsy Market, By Region, From 2020 to 2025 (USD Million)
  20. Latin America Ovarian Cancer Market, By Type Of Treatment, From 2020 to 2025 (USD Million)
  21. Latin America Chemotherapy Market, By Region, From 2020 to 2025 (USD Million)
  22. Latin America Radiation Therapy Market, By Region, From 2020 to 2025 (USD Million)
  23. Latin America Hormonal Therapy Market, By Region, From 2020 to 2025 (USD Million)
  24. Latin America Surgery Market, By Region, From 2020 to 2025 (USD Million)
  25. Latin America Immunotherapy Market, By Region, From 2020 to 2025 (USD Million)
  26. Latin America Targeted Therapy Market, By Region, From 2020 to 2025 (USD Million)
  27. Brazil Ovarian Cancer Market, By Stage Of Cancer, From 2020 to 2025 (USD Million)
  28. Brazil Ovarian Cancer Market, By Cancer Type, From 2020 to 2025 (USD Million)
  29. Brazil Ovarian Cancer Market, By Diagnosis, From 2020 to 2025 (USD Million)
  30. Brazil Ovarian Cancer Market, By Type Of Treatment, From 2020 to 2025 (USD Million)
  31. Argentina Ovarian Cancer Market, By Stage Of Cancer, From 2020 to 2025 (USD Million)
  32. Argentina Ovarian Cancer Market, By Cancer Type, From 2020 to 2025 (USD Million)
  33. Argentina Ovarian Cancer Market, By Diagnosis, From 2020 to 2025 (USD Million)
  34. Argentina Ovarian Cancer Market, By Type Of Treatment, From 2020 to 2025 (USD Million)
  35. Mexico Ovarian Cancer Market, By Stage Of Cancer, From 2020 to 2025 (USD Million)
  36. Mexico Ovarian Cancer Market, By Cancer Type, From 2020 to 2025 (USD Million)
  37. Mexico Ovarian Cancer Market, By Diagnosis, From 2020 to 2025 (USD Million)
  38. Mexico Ovarian Cancer Market, By Type Of Treatment, From 2020 to 2025 (USD Million)
  39. Rest of Latin America Ovarian Cancer Market, By Stage Of Cancer, From 2020 to 2025 (USD Million)
  40. Rest of Latin America Ovarian Cancer Market, By Cancer Type, From 2020 to 2025 (USD Million)
  41. Rest of Latin America Ovarian Cancer Market, By Diagnosis, From 2020 to 2025 (USD Million)
  42. Rest of Latin America Ovarian Cancer Market, By Type Of Treatment, From 2020 to 2025 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample